CLINICAL_TRIALS
trial_result
· 2021-06-08
Clinical Trial Update: Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine [Phase 2]
Summary
A Phase II study assessing safety and immunogenicity of a chikungunya vaccine has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Snippet
Sponsor: Themis Bioscience GmbH | Conditions: Chikungunya Virus Infection | Phase 2 | Status: COMPLETED | Results posted: 2021-06-08